Ignite Creation Date:
2025-12-24 @ 7:58 PM
Ignite Modification Date:
2025-12-25 @ 5:32 PM
Study NCT ID:
NCT01662804
Status:
COMPLETED
Last Update Posted:
2021-05-27
First Post:
2012-08-07
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-08-06
Start Date Type:
ACTUAL
Primary Completion Date:
2021-05-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-05-25
Completion Date Type:
ACTUAL
First Submit Date:
2012-08-07
First Submit QC Date:
None
Study First Post Date:
2012-08-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-05-26
Last Update Post Date:
2021-05-27
Last Update Post Date Type:
ACTUAL